| Literature DB >> 36250089 |
Po-Chin Kuo1, Jia-Horung Hung2,3, Yu-Chen Su2, Ching-Ju Fang4,5, Chaw-Ning Lee6,7, Yi-Hsun Huang2, Shih-Chieh Shao7,8, Edward Chia-Cheng Lai7.
Abstract
Background: Phacoemulsification is an effective and widely performed technique in cataract surgery, but the comparative anatomical outcomes, including endothelial cell loss (ECL), central corneal thickness (CCT), and central macular thickness (CMT), between high-flow and low-flow phacoemulsification cataract surgery remain unclear.Entities:
Keywords: cataract surgery; central corneal thickness; central macular thickness; endothelial cell loss; fluidics; meta-analysis; phacoemulsification; systematic review
Year: 2022 PMID: 36250089 PMCID: PMC9554630 DOI: 10.3389/fmed.2022.1021941
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
Characteristics of comparative studies regarding high-low and low-flow aspiration flow settings of patients who underwent phacoemulsification.
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| Baradaran-Rafii et al. (2009) ( | Iran | 50 to 70-year-old, senile cataract with 3+ nuclear sclerosis | WhiteStar®, | ECL (postoperative week 1, 6, 12) | ECL: low-flow 9.5%, |
| Chang et al. (2017) ( | Sweden | 50 to 85-year-old, senile cataract | Infiniti®, | 1. ECL (postoperative month 3) | 1. ECL: low-flow 194 cells/mm2, |
| Das et al. (2015) ( | India | Senile cataract (LOCS III grade 2–4) | Infiniti®, | 1. ECL (postoperative week 2, 6) | 1. ECL: low-flow 245.82 cells/mm2, |
| Schriefl et al. (2014) ( | Austria | Senile cataract | OS3 base module®, | ECL (postoperative week 1, month 18) | ECL: low-flow 1.8%, high-flow 4.46% at week 1 ( |
| Vasavada et al. (2010) ( | India | Senile cataract (Emery-Little classification grade 2–3) | Infiniti®, | 1. ECL (postoperative month 3) | 1. ECL: low-flow 4.67%, |
| Vasavada et al. (2014) ( | India | Senile cataract, LOCS III grade 2–3 | Infiniti®, | 1. ECL (postoperative month 3) | 1. ECL: No statistically significant percentage change at month 3 (no exact value provided) |
ECL, endothelial cell loss; CCT, central corneal thickness; CMT, central macular thickness; LOCS, lens opacities classification system.
Figure 1Endothelial cell loss (ECL). (A) Postoperative days 2–14 [%]. (B) Postoperative days 15–42 [%]. (C) Postoperative day 43 - month 18 [%].
Figure 2Change in central corneal thickness (CCT). (A) Postoperative day 1 [μm]. (B) Postoperative days 2–14 [μm]. (C) Postoperative days 15–42 [μm].
Figure 3Change in central macular thickness (CMT), postoperative days 15–42 [μm].
Summary of anatomical outcomes from low-flow compared with high-flow phacoemulsification.
|
|
| ||||||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
| |||||||
| Postoperative day 1 | |||||||
| No RCTs | NA | NA | NA | NA | NA | NA | NA |
| Postoperative days 2–14 | |||||||
| 304 | Very serious | Not serious | Not serious | Serious | Not detected | −1.63 % | ⊕○○○ |
| Postoperative days 15–42 | |||||||
| 190 | Very serious | Not serious | Not serious | Serious | Not detected | −0.65 % | ⊕○○○ |
| Postoperative day 43 to month 18 | |||||||
| 267 | Very serious | Not serious | Not serious | Serious | Not detected | −0.35 % | ⊕○○○ |
|
| |||||||
| Postoperative day 1 | |||||||
| 123 | Very serious | Serious | Not serious | Serious | Not detected | −16.37 μm | ⊕○○○ |
| Postoperative days 2–14 | |||||||
| 210 | Very serious | Serious | Not serious | Serious | Not detected | −10.92 μm | ⊕○○○ |
| Postoperative days 15–42 | |||||||
| 253 | Serious | Not serious | Not serious | Serious | Not detected | −2.76 μm | ⊕⊕○○ |
| Postoperative day 43 to month 18 | |||||||
| No RCTs | NA | NA | NA | NA | NA | NA | NA |
|
| |||||||
| Postoperative days 1–14 | |||||||
| No RCTs | NA | NA | NA | NA | NA | NA | NA |
| Postoperative days 15–42 | |||||||
| 173 | Serious | Not serious | Not serious | Serious | Not detected | −4.58 μm | ⊕⊕○○ |
| Postoperative day 43 to month 18 | |||||||
| No RCTs | NA | NA | NA | NA | NA | NA | NA |
Risk of bias: no concerns (≥75% cells with low or no risk of bias and no cell with high risk of bias), serious concerns (no cell with high risk of bias and >25% cells with unclear risk of bias, or at least one but <25% cells with high risk of bias and ≤ 25% cells with unclear risk of bias), and very serious concerns (≥25% cells with high risk of bias, or at least one cell with high risk of bias and ≥25% cells with unclear risk of bias).
Inconsistency: I2 >50%.
Imprecision: total study participants < 400.